Treatment of primary CLL cells with TAK-659 0.1 μM for 1 hour resulted in a strong reduction of the migratory capacity toward CXCL12, CXCL13 and the BMSC cell line, HS-5 (Figures 5A, 5B and 5C). The gene discussed is CXCL13; the disease is B-cell chronic lymphocytic leukemia.